Please check your internet connection and try again.
# Meftal spas
## Overview
Meftal spas is a combination product containing mefenamic acid (a nonsteroidal anti-inflammatory drug, NSAID) and dicyclomine hydrochloride (an anticholinergic antispasmodic). Mefenamic acid provides analgesic and anti-inflammatory effects, while dicyclomine reduces smooth muscle spasms.
## Primary Indications
* Symptomatic treatment of abdominal pain and cramps associated with gastrointestinal disorders.
* Primary dysmenorrhea.
## Adult Dosing
* **Gastrointestinal disorders/Dysmenorrhea:** 1 tablet (250 mg mefenamic acid / 20 mg dicyclomine) three times daily, usually for 2-5 days.
* Maximum dose of mefenamic acid is typically 500 mg every 6 hours, not to exceed 1000 mg per day. Dicyclomine dose is generally not to exceed 80 mg per day.
## Pediatric Dosing
Dosing for meftal spas in pediatric populations is not well-established and should be determined by a healthcare provider based on the child's weight and clinical condition. Mefenamic acid doses in children typically range from 5-7 mg/kg/dose every 6-8 hours. Dicyclomine doses for children are usually 0.5-1 mg/kg/day divided into 3-4 doses.
## Dose Adjustments
* **Renal Impairment:** Use with caution; reduce dose if necessary. Mefenamic acid is renally eliminated and can cause renal damage.
* **Hepatic Impairment:** Use with caution; may require dose reduction.
* **Elderly:** Use with caution, especially in those with compromised renal or hepatic function.
## Contraindications
* Hypersensitivity to mefenamic acid, dicyclomine, or other NSAIDs/anticholinergics.
* Active or history of gastrointestinal bleeding or ulceration.
* Severe renal or hepatic impairment.
* Glaucoma (narrow-angle).
* Myasthenia gravis.
* Obstructive uropathy or gastrointestinal obstruction.
* Severe ulcerative colitis or toxic megacolon.
* Infants < 6 months of age (due to potential for respiratory depression with dicyclomine).
* Third trimester of pregnancy.
## Adverse Effects
* **Mefenamic Acid:** Dyspepsia, nausea, vomiting, abdominal pain, diarrhea, constipation, rash, dizziness, headache, tinnitus, anemia, fluid retention, hypertension, renal impairment, gastrointestinal bleeding, ulceration.
* **Dicyclomine:** Dry mouth, blurred vision, urinary retention, constipation, drowsiness, confusion, dizziness, tachycardia, palpitations.
## Key Drug Interactions
* **NSAIDs (e.g., aspirin, ibuprofen):** Increased risk of gastrointestinal bleeding and renal toxicity.
* **Anticoagulants (e.g., warfarin):** Increased risk of bleeding.
* **Corticosteroids:** Increased risk of gastrointestinal ulceration and bleeding.
* **ACE inhibitors/ARBs/Diuretics:** Reduced antihypertensive effect and increased risk of renal impairment.
* **Lithium:** Increased lithium levels.
* **Anticholinergics:** Additive anticholinergic effects.
* **Other CNS depressants:** Increased sedative effects.
## Monitoring
* **Renal function:** Monitor BUN and creatinine, especially with long-term use or in patients with risk factors.
* **Hepatic function:** Monitor LFTs if indicated.
* **Gastrointestinal symptoms:** Assess for signs of bleeding or ulceration.
* **Blood pressure:** Monitor for potential increase.
* **Signs of anticholinergic effects:** Monitor for dry mouth, blurred vision, urinary retention, constipation, and confusion, particularly in the elderly.
## Clinical Pearls
* Administer with food or milk to minimize gastrointestinal upset.
* Avoid concurrent use with other NSAIDs.
* Discontinue if signs of gastrointestinal bleeding or serious adverse reactions occur.
* Use cautiously in patients with asthma, cardiovascular disease, or a history of peptic ulcer disease.
* Dicyclomine can cause drowsiness; advise patients to avoid activities requiring mental alertness until they know how the drug affects them.
***
*This information is intended for healthcare professionals and does not substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines before making any clinical decisions.*
